Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: A meta-analysis of randomized controlled trials

Wenzhen Yuan, Kehu Yang, Bin Ma, Yumin Li, Quanlin Guan, Donghai Wang, Lijuan Yang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Moxifloxacin-based triple therapy has been suggested as an alternative first line therapy to clarithromycin-based triple therapy for Helicobacter pylori infection. Aims: To systematically review the efficacy and tolerance of moxifloxacin-based triple therapy, and to conduct a meta-analysis of studies comparing this regimen with clarithromycin-based triple therapy. Methods: A search of The Cochrane Library, PUBMED, EMBASE, EBM Review databases, Science Citation Index Expanded, and CMB (Chinese Biomedical Literature Database) was performed. Randomized controlled trials comparing moxifloxacin-based triple therapy to gold standard triple therapy in the first-line treatment of Helicobacter pylori infection were selected for meta-analysis. Relative risk was used as a measure of the effect of the two above-mentioned regimens with a fixed-effects model using the methods of DerSimonian and Laird. Results: Four randomized controlled trials totaling 772 patients were included. The meta-analysis showed that the mean eradication rate was 84.1 (318/378) in the moxifloxacin-based triple therapy group and 73.6 (290/394) in the clarithromycin-based triple therapy group; there was statistical significance between the two groups (RR, 1.13; 95% CI, 1.01, 1.27; P=0.04). There were no statistically significant difference in the overall side effects (RR, 0.61; 95% CI, 0.25, 1.48; P<0.28). Conclusions: Moxifloxacin-based triple therapy is more effective and does not increase the incidence of overall side effects compared to clarithromycin-based triple therapy in the treatment of H. pylori infection.

Original languageEnglish (US)
Pages (from-to)2069-2076
Number of pages8
JournalInternal Medicine
Volume48
Issue number24
DOIs
StatePublished - 2009

Fingerprint

Clarithromycin
Helicobacter Infections
Helicobacter pylori
Meta-Analysis
Randomized Controlled Trials
Therapeutics
Group Psychotherapy
moxifloxacin
Databases
Libraries

Keywords

  • Clarithromycin
  • First-line treatment
  • Helicobacter pylori
  • Meta-analysis
  • Moxifloxacin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection : A meta-analysis of randomized controlled trials. / Yuan, Wenzhen; Yang, Kehu; Ma, Bin; Li, Yumin; Guan, Quanlin; Wang, Donghai; Yang, Lijuan.

In: Internal Medicine, Vol. 48, No. 24, 2009, p. 2069-2076.

Research output: Contribution to journalArticle

Yuan, Wenzhen ; Yang, Kehu ; Ma, Bin ; Li, Yumin ; Guan, Quanlin ; Wang, Donghai ; Yang, Lijuan. / Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection : A meta-analysis of randomized controlled trials. In: Internal Medicine. 2009 ; Vol. 48, No. 24. pp. 2069-2076.
@article{ba75a69bc8f846a0b0c230ad5b2d4c8b,
title = "Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: A meta-analysis of randomized controlled trials",
abstract = "Background: Moxifloxacin-based triple therapy has been suggested as an alternative first line therapy to clarithromycin-based triple therapy for Helicobacter pylori infection. Aims: To systematically review the efficacy and tolerance of moxifloxacin-based triple therapy, and to conduct a meta-analysis of studies comparing this regimen with clarithromycin-based triple therapy. Methods: A search of The Cochrane Library, PUBMED, EMBASE, EBM Review databases, Science Citation Index Expanded, and CMB (Chinese Biomedical Literature Database) was performed. Randomized controlled trials comparing moxifloxacin-based triple therapy to gold standard triple therapy in the first-line treatment of Helicobacter pylori infection were selected for meta-analysis. Relative risk was used as a measure of the effect of the two above-mentioned regimens with a fixed-effects model using the methods of DerSimonian and Laird. Results: Four randomized controlled trials totaling 772 patients were included. The meta-analysis showed that the mean eradication rate was 84.1 (318/378) in the moxifloxacin-based triple therapy group and 73.6 (290/394) in the clarithromycin-based triple therapy group; there was statistical significance between the two groups (RR, 1.13; 95{\%} CI, 1.01, 1.27; P=0.04). There were no statistically significant difference in the overall side effects (RR, 0.61; 95{\%} CI, 0.25, 1.48; P<0.28). Conclusions: Moxifloxacin-based triple therapy is more effective and does not increase the incidence of overall side effects compared to clarithromycin-based triple therapy in the treatment of H. pylori infection.",
keywords = "Clarithromycin, First-line treatment, Helicobacter pylori, Meta-analysis, Moxifloxacin",
author = "Wenzhen Yuan and Kehu Yang and Bin Ma and Yumin Li and Quanlin Guan and Donghai Wang and Lijuan Yang",
year = "2009",
doi = "10.2169/internalmedicine.48.2344",
language = "English (US)",
volume = "48",
pages = "2069--2076",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "24",

}

TY - JOUR

T1 - Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection

T2 - A meta-analysis of randomized controlled trials

AU - Yuan, Wenzhen

AU - Yang, Kehu

AU - Ma, Bin

AU - Li, Yumin

AU - Guan, Quanlin

AU - Wang, Donghai

AU - Yang, Lijuan

PY - 2009

Y1 - 2009

N2 - Background: Moxifloxacin-based triple therapy has been suggested as an alternative first line therapy to clarithromycin-based triple therapy for Helicobacter pylori infection. Aims: To systematically review the efficacy and tolerance of moxifloxacin-based triple therapy, and to conduct a meta-analysis of studies comparing this regimen with clarithromycin-based triple therapy. Methods: A search of The Cochrane Library, PUBMED, EMBASE, EBM Review databases, Science Citation Index Expanded, and CMB (Chinese Biomedical Literature Database) was performed. Randomized controlled trials comparing moxifloxacin-based triple therapy to gold standard triple therapy in the first-line treatment of Helicobacter pylori infection were selected for meta-analysis. Relative risk was used as a measure of the effect of the two above-mentioned regimens with a fixed-effects model using the methods of DerSimonian and Laird. Results: Four randomized controlled trials totaling 772 patients were included. The meta-analysis showed that the mean eradication rate was 84.1 (318/378) in the moxifloxacin-based triple therapy group and 73.6 (290/394) in the clarithromycin-based triple therapy group; there was statistical significance between the two groups (RR, 1.13; 95% CI, 1.01, 1.27; P=0.04). There were no statistically significant difference in the overall side effects (RR, 0.61; 95% CI, 0.25, 1.48; P<0.28). Conclusions: Moxifloxacin-based triple therapy is more effective and does not increase the incidence of overall side effects compared to clarithromycin-based triple therapy in the treatment of H. pylori infection.

AB - Background: Moxifloxacin-based triple therapy has been suggested as an alternative first line therapy to clarithromycin-based triple therapy for Helicobacter pylori infection. Aims: To systematically review the efficacy and tolerance of moxifloxacin-based triple therapy, and to conduct a meta-analysis of studies comparing this regimen with clarithromycin-based triple therapy. Methods: A search of The Cochrane Library, PUBMED, EMBASE, EBM Review databases, Science Citation Index Expanded, and CMB (Chinese Biomedical Literature Database) was performed. Randomized controlled trials comparing moxifloxacin-based triple therapy to gold standard triple therapy in the first-line treatment of Helicobacter pylori infection were selected for meta-analysis. Relative risk was used as a measure of the effect of the two above-mentioned regimens with a fixed-effects model using the methods of DerSimonian and Laird. Results: Four randomized controlled trials totaling 772 patients were included. The meta-analysis showed that the mean eradication rate was 84.1 (318/378) in the moxifloxacin-based triple therapy group and 73.6 (290/394) in the clarithromycin-based triple therapy group; there was statistical significance between the two groups (RR, 1.13; 95% CI, 1.01, 1.27; P=0.04). There were no statistically significant difference in the overall side effects (RR, 0.61; 95% CI, 0.25, 1.48; P<0.28). Conclusions: Moxifloxacin-based triple therapy is more effective and does not increase the incidence of overall side effects compared to clarithromycin-based triple therapy in the treatment of H. pylori infection.

KW - Clarithromycin

KW - First-line treatment

KW - Helicobacter pylori

KW - Meta-analysis

KW - Moxifloxacin

UR - http://www.scopus.com/inward/record.url?scp=74549134768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549134768&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.48.2344

DO - 10.2169/internalmedicine.48.2344

M3 - Article

C2 - 20009394

AN - SCOPUS:74549134768

VL - 48

SP - 2069

EP - 2076

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 24

ER -